Regenxbio Inc. (RGNX) PT Raised to $40 at Stifel

Go back to Regenxbio Inc. (RGNX) PT Raised to $40 at Stifel

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

March 6, 2024 11:21 PM EST

ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting... More

REGENXBIO Announces Proposed Public Offering of Common Stock

March 6, 2024 4:10 PM EST

ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or... More